

## Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naïve (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D

**Authors:** Richard Greil<sup>1</sup>, Shuo Ma<sup>2</sup>, Talha Munir<sup>3</sup>, Masa Lasica<sup>4</sup>, Mazyar Shadman<sup>5</sup>, Emmanuelle Ferrant<sup>6</sup>, Ian W. Flinn<sup>7</sup>, Wojciech Janowski<sup>8</sup>, Monica Tani<sup>9</sup>, Tadeusz Robak<sup>10</sup>, Jennifer R. Brown<sup>11</sup>, Constantine S. Tam<sup>12</sup>, Tian Tian<sup>13</sup>, Emily Mantovani<sup>14</sup>, Stephanie Agresti<sup>15</sup>, Linlin Xu<sup>16</sup>, Aileen Cohen<sup>17</sup>, Wojciech Jurczak<sup>18</sup>, Paolo Ghia<sup>19</sup>

**Affiliations:** <sup>1</sup>Third Medical Department with Hematology Medical Oncology Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg; <sup>2</sup>Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>3</sup>Leeds Teaching Hospitals NHS Trust, Leeds, UK; <sup>4</sup>St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; <sup>5</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; <sup>6</sup>Département Hématologie, CHU de Lyon-Sud, Lyon-Sud, France; <sup>7</sup>Tennessee Oncology/OneOncology, Nashville, TN, USA; <sup>8</sup>Calvary Mater Newcastle Hospital, Waratah, NSW, Australia; <sup>9</sup>Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy; <sup>10</sup>Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland; <sup>11</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>12</sup>Alfred Hospital and Monash University, Melbourne, VIC, Australia; <sup>13</sup>BeiGene USA Inc, San Mateo, CA, USA; <sup>14</sup>BeiGene USA Inc, San Mateo, CA, USA; <sup>15</sup>BeiGene USA Inc, San Mateo, CA, USA; <sup>16</sup>BeiGene USA Inc, San Mateo, CA, USA; <sup>17</sup>BeiGene USA Inc, San Mateo, CA, USA; <sup>18</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland; <sup>19</sup>IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.

### ABSTRACT

**Introduction:** Combination BCL2/BTK inhibitor treatment (tx) has been tolerable and led to durable responses in patients (pts) with CLL/SLL. Here, initial results are presented in pts with TN CLL/SLL with del(17p) and/or TP53 mutation who received zanu+ven in SEQUOIA arm D.

**Methods:** SEQUOIA (NCT03336333) is an open-label, global, phase 3 study; arm D includes nonrandomized pts aged  $\geq 65$  y (or 18-64 y with comorbidities) who met iwCLL 2008 criteria for tx. After a 3-cycle zanu 160 mg BID lead-in, pts had 24 cycles of zanu+ven (ramp-up to 400 mg QD), then zanu monotherapy until PD, unacceptable toxicity, or early dose-stopping rules for zanu or ven were met (simultaneous CR/CR with incomplete hematopoietic recovery [CRI] and undetectable minimal residual disease [uMRD]  $< 1 \times 10^{-4}$  by flow cytometry in peripheral blood [PB] and bone marrow [BM] on 2 consecutive tests  $\geq 12$  wk apart). Responses were investigator assessed per modified iwCLL and Lugano 2014 criteria (SLL), with PB MRD assessment every 3 cycles for 2 y, then every 6 cycles. Safety per CTCAE and tumor lysis syndrome (TLS) risk per Cairo-Bishop criteria were assessed. Pts with high TLS risk had any lymph node  $\geq 10$  cm or  $\geq 5$  cm with absolute lymphocyte count  $\geq 25 \times 10^9/L$ .

**Results:** From Nov 2019-Jun 2022, 66 pts with centrally assessed del(17p) and/or TP53 mutation were enrolled. By Oct 31, 2023 (median follow-up, 28.6 mo; range, 0.4-47.4), 55/63 pts (87%) who initiated zanu+ven remained on tx (16 zanu+ven; 39 zanu monotherapy after ven). Six pts discontinued the study (4 deaths; 1 withdrawal; 1 loss to follow-up); 3 discontinued tx during zanu lead-in. In 65 response-evaluable pts, ORR was 100% and CR+CRI rate was 45%. uMRD occurred in 48% of pts in  $\geq 1$  PB sample. Median PFS was not reached; 36-mo estimated PFS was 92% (95% CI, 81%-97%). The most common all-grade nonhematologic TEAEs were COVID-19 (55%), diarrhea (41%), contusion (29%), and nausea (29%).

Grade  $\geq 3$  nonhematologic TEAEs occurred in 44%; the most common were diarrhea (8%) and hypertension (8%). Neutropenia was the most common all-grade (21%) and grade  $\geq 3$  (17%) hematologic toxicity. At screening, 35% of pts had high TLS risk; this decreased to 3% after 3 zanu lead-in cycles. No TLS occurred.

**Conclusions:** Preliminary data show promising efficacy and good tolerability of zanu+ven in pts with high-risk TN CLL/SLL with del(17p) and/or *TP53* mutation. The safety profile of zanu+ven was consistent with prior studies, with no new safety signals identified.